Search Results

SonoVascular, Inc. has executed an exclusive clinical supply agreement with Lantheus Holdings, Inc. to use Lantheus’ microbubbles in combination with SonoVascular’s SonoThrombectomy System to treat deep vein thrombosis and pulmonary embolism.

Lantheus Holdings, Inc. announced Jeffrey S. Humphrey, MD has been appointed Chief Medical Officer and Jean-Claude Provost, MD has been named Chief Science Officer, effective May 28, 2024.

Lantheus Holdings, Inc. today announced statistically significant topline results from the pivotal phase 3 SPLASH study evaluating the efficacy and safety of 177 Lu-PNT2002, a prostate-specific membrane antigen (PSMA)-targeted radioligand therapy (RLT).

Radiopharm Theranostics Limited, a developer of diagnostic and therapeutic radiopharmaceutical products, has entered into strategic agreements with Lantheus Holdings, Inc., a leading radiopharmaceutical-focused company, and its affiliates.

POINT Biopharma Global Inc. (“POINT”) (NASDAQ: PNT), a company accelerating the discovery, development, and global access to life-changing radiopharmaceuticals, today announced that the closing conditions, including Hart-Scott-Rodino antitrust clearance, have been met for the previously announced agreements with Lantheus Holdings Inc. (NASDAQ: LNTH).

Now that they’ve received the go-signal from both U.S. and EU anti-trust regulators, Novo Holdings and Catalent expect to wrap up their deal in the coming days.

While the candidate was effective in Phase III results, Point’s stock price fell following the announcement.